Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarctionThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.

K. Sanganalmath, Santosh; Barta, Judit; Takeda, Nobuakira; Kumamoto, Hideo; S. Dhalla, Naranjan

doi:10.1139/y08-005

Public

Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarctionThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.

Published in Canadian Journal of Physiology and Pharmacology • Apr 1, 2008

Authors:

Santosh K. Sanganalmath

Judit Barta

Nobuakira Takeda

Abstract

Antiplatelet agents such as sarpogrelate (SAR), a 5-hydroxytryptamine antagonist, and cilostazol (CIL), a phosphodiesterase-III inhibitor, are used in the management of peripheral vascular disease. In this study, we tested the hypothesis that both SAR and CIL prevent cardiac remodeling and improve c...

Subject

Medicine

Cardiology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!